City-wide Surveillance for the Occurrence of Respiratory Syncytial Virus(RSV) Respiratory Tract Infections in a Population of High Risk Infants ≤32 weeks Gestational Age † 1453

被引：0
|
作者：
Janine Y Khan
Beverly S Brozanski
机构：
[1] RSV Pittsburgh Consortium,Department of Pediatrics
[2] University of Pittsburgh,undefined
[3] Magee-Womens Research Institute,undefined
来源：
Pediatric Research | 1998年 / 43卷 / Suppl 4期
关键词：
D O I：
10.1203/00006450-199804001-01474
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：248 / 248
相关论文
共 50 条
  • [41] An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study
    Michela Servadio
    Marco Finocchietti
    Chiara Vassallo
    Riccardo Cipelli
    Franca Heiman
    Giulia Di Lucchio
    Bianca Oresta
    Antonio Addis
    Valeria Belleudi
    Italian Journal of Pediatrics, 50
  • [42] Palivizumab for respiratory syncytial virus (RSV) prophylaxis of high-risk infants in a medicaid health maintenance organization (HMO)
    Schaffer, M
    Greenspan, JS
    Amaya, MA
    Vojta, D
    PEDIATRIC RESEARCH, 2000, 47 (04) : 322A - 322A
  • [43] Urinary tract infection one must exclude in febrile infants less than 3 months of age with respiratory syncytial virus (RSV)
    Muniz, AE
    ANNALS OF EMERGENCY MEDICINE, 2005, 46 (03) : S83 - S83
  • [44] Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Hospitalizations in Preterm Infants Born to 290/7 to 316/7 Weeks of Gestational Age
    Zamur, Elifcan
    Uygur, Ozgun
    Karadag-Oncel, Eda
    Gunes, Sezgin
    Sahin, Suzan
    Demirel, Melike Kefeli
    Engur, Defne
    Oncel, Mehmet Yekta
    JOURNAL OF PEDIATRIC INFECTIOUS DISEASES, 2024,
  • [45] ASSESSMENT OF THE COST-EFFECTIVENESS OF RISK FACTOR GUIDED PROPHYLAXIS WITH PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN COLOMBIAN INFANTS BORN AT 32-35 WEEKS' GESTATIONAL AGE
    Rodriguez-Martinez, C. E.
    Ordonez, J.
    Carbonell-Estrany, X.
    Fullarton, J.
    Keary, I
    Rodgers-Gray, B.
    D'Apremont, I
    Espinosa, S. M.
    Ribeiro, P. A.
    Stein, R.
    Vain, N.
    Tarride, J. E.
    Paes, B.
    VALUE IN HEALTH, 2023, 26 (12) : S156 - S156
  • [46] Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland A Prospective Study
    Sheridan-Pereira, Margaret
    Murphy, Joan
    Sloan, Julie
    Crispino, Gloria
    Leahy, Anne
    Corcoran, J. David
    Dempsey, Eugene
    Elnazir, Basil
    Gavin, Patrick
    Sharif, Farhana
    Satas, Salius
    Gul, Rizwan
    Murphy, John
    Gormally, Siobhan
    Shanaa, Issam
    Waldron, David
    Mc Mahon, Paul
    Carson, John
    Blanken, Maarten
    Bont, Louis
    Paes, Bosco
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (01) : 19 - 24
  • [47] Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization
    Helfrich, Alison M.
    Nylund, Cade M.
    Eberly, Matthew D.
    Eide, Matilda B.
    Stagliano, David R.
    EARLY HUMAN DEVELOPMENT, 2015, 91 (09) : 541 - 546
  • [48] INTRAVENOUS GAMMA-GLOBULIN (IVIG) FOR PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) DISEASE IN HIGH-RISK INFANTS
    GROOTHUIS, J
    RODRIGUEZ, W
    HALL, C
    HEMMING, V
    PEDIATRIC RESEARCH, 1990, 27 (04) : A171 - A171
  • [49] Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Robinson, Joan L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1631 - 1632
  • [50] European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data
    Simoes, Eric A. F.
    Carbonell-Estrany, Xavier
    Fullarton, John R.
    Rossi, Giovanni A.
    Barberi, Ignazio
    Lanari, Marcello
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2011, 24 (01): : 152 - 157
12345